Table 1. Characteristics of the patients according to presence or absence of TERT promoter mutations (n=305).
| Variable | Overall series (n=305) | TERT promoter mutated n=179 (59%) | TERT promoter non-mutated n=126 (41%) | P-value |
|---|---|---|---|---|
| Age | ||||
| >60 years* | 187/305 (61%) | 117 (65%) | 70 (55%) | 0.08 |
| Gender | ||||
| Male* | 242/305 (79%) | 154 (86%) | 88 (70%) | 0.001 |
| Aetiology | ||||
| HCV* | 68/301 (26%) | 49 (28%) | 19 (15%) | 0.03 |
| HBV* | 67/303 (22%) | 26 (15%) | 41 (33%) | <0.0001 |
| Alcohol* | 118/300 (39%) | 80 (46%) | 38 (31%) | 0.03 |
| Haemochromatosis* | 19/299 (6%) | 12 (7%) | 7 (6%) | 0.84 |
| Miscellaneous* | 13/291 (5%) | 7 (4%) | 5 (4%) | 0.74 |
| Unknown* | 46/291 (16%) | 22 (13%) | 24 (20%) | 0.14 |
| Tumour size | ||||
| <5 cm* | 127/303 (42%) | 87 (49%) | 40 (32%) | 0.01 |
| Tumour number | ||||
| Single* | 212/304 (70%) | 118 (66%) | 94 (75%) | 0.39 |
| Vascular invasion | ||||
| Microvascular* | 161/300 (54%) | 91 (52%) | 70 (56%) | 0.7 |
| Macrovascular* | 46/300 (15%) | 28 (16%) | 18 (14%) | 0.94 |
| Differentiation | ||||
| Edmonson I–II* | 143/295 (48%) | 83 (48%) | 60 (49%) | 0.70 |
| Edmonson III–IV* | 152/295 (52%) | 91 (52%) | 61 (51%) | |
| Metavir score (non-tumour liver) | ||||
| F0–F1* | 106/299 (35%) | 58 (33%) | 48 (38%) | 0.21 |
| F2–F3* | 83/299 (28%) | 45 (26%) | 38 (30%) | |
| F4* | 110/299 (37%) | 71 (41%) | 39 (32%) | |
| Preoperative AFP | ||||
| >20 ng ml−1* | 123/274 (45%) | 60 (38%) | 63 (54%) | 0.01 |
| G1-G6 classification | ||||
| G1* | 22/286 (8%) | 9 (5%) | 13 (11%) | 0.12 |
| G2* | 22/286 (8%) | 13 (8%) | 9 (8%) | |
| G3* | 53/286 (18%) | 37 (22%) | 16 (14%) | |
| G4* | 93/286 (32%) | 49 (28%) | 44 (38%) | |
| G5* | 62/286 (22%) | 41 (24%) | 21 (19%) | |
| G6* | 34/286 (12%) | 22 (13%) | 12 (10%) | |
| CTNNB1 | ||||
| Mutated* | 101/304 (33%) | 75 (42%) | 26 (21%) | <0.0001 |
| TP53 | ||||
| Mutated* | 60/302 (20%) | 34 (19%) | 26 (21%) | 0.73 |
| Events | ||||
| Median follow-up (months)† | 34/260 (17–56) | 33 (16–54) | 36 (22–58) | 0.13 |
| Tumour-related death<5 years‡ | 92/260 (35%) | 57 (37%) | 35 (33%) | 0.26 |
| Overall recurrence<5 years‡ | 138/260 (53%) | 84 (55%) | 54 (50%) | 0.28 |
AFP, alpha-fetoprotein; HBV, hepatitis B; TERT, telomerase reverse-trancriptase.
*Expressed as number (%) and analysed using the χ2-test (group size of >5) with Yates’ continuity correction or Fisher’s exact test (group size of ≤5) except for multiple variable comparisons (χ2-test two sided). P-values were adjusted for multiple comparisons using Monte–Carlo resampling.
†Expressed in months (median, 25th and 75th percentile) and analysed using the Kruskall–Wallis test.
‡Patients treated by surgical curative resection (R0) with available follow-up were included in the survival analysis (n=260), and survival analysis was performed using the log-rank test.